In December 2019, cases of severe acute respiratory syndrome (SARS) emerged from Wuhan, China, and were after associated with a novel Coronavirus (SARS-CoV-2). Since then, reports have described neurological manifestations in addition to the typical clinical symptoms of the Coronavirus disease 2019 (COVID-19), represented by fever, cough, diarrhea, and fatigue. Hospitalized patients with COVID-19, especially those with severe disease, can display neurological disorders as shown by [@bib0050], such as acute cerebrovascular disease in up to 5.7%, impaired consciousness in 14.8%, and skeletal muscle injury in 19.3% of cases. Nonetheless, COVID-19 seems to be associated with a wide spectrum of neurological manifestations, including meningoencephalitis ([@bib0015], [@bib0030], [@bib0055]), encephalomyelitis ([@bib0090]), Guillain-Barré Syndrome (GBS) ([@bib0080], [@bib0025], [@bib0060], [@bib0010], [@bib0040]), and perfusion abnormalities in brain magnetic resonance imaging (MRI) ([@bib0035]). However, opposed to prolonged viral RNA detection in nasopharyngeal swabs (≥20 days after symptoms onset) and in feces ([@bib0075]), attempts of our research group and others to detect SARS-CoV-2 RNA in the cerebrospinal fluid (CSF) of patients with neurological manifestations indicative of central nervous system (CNS) infection has been shown frustrated so far, except for one case of meningoencephalitis ([Table 1](#tbl0005){ref-type="table"} ). CSF analysis showed normal to mild elevated protein levels, and pleocytosis was particularly observed in the cases of meningoencephalitis ([Table 2](#tbl0010){ref-type="table"} ). Indeed, CNS infiltrate was predominantly constituted by mononuclear cells, which is compatible with viral infection ([Table 2](#tbl0010){ref-type="table"}). [@bib0065] hypothesized a three-step model to explain the CNS invasion by SARS-CoV-2 and the resulting neurological involvement, suggesting that the viral load in CSF progressively increases and it triggers an inflammatory response, but the viral clearance precede the occurrence of indirect SARS-CoV-2 effects on the CNS. Neurological manifestations in COVID-19 generally arise between 1 to 14 days after the beginning of infectious symptoms ([@bib0050]), and it has been predicted a mean incubation period of 5 days (time between infection and symptoms onset) ([@bib0045]). Therefore, considering the time between infection and the lumbar puncture ([Table 1](#tbl0005){ref-type="table"}), CSF may be devoid of virus particles, even if patients have a positive result for SARS-CoV-2 RNA on nasopharyngeal swabs. Head computed tomography or MRI data showing distinct patterns of neurological damage ([@bib0005], [@bib0030], [@bib0035], [@bib0090]) and the undetectable levels of SARS-CoV-2 RNA in CSF promptly collected at the onset of neurological symptoms ([Table 1](#tbl0005){ref-type="table"}) corroborate with this picture. Moreover, the suggestive para-infectious process of GBS cases ([@bib0010], [@bib0025], [@bib0060], [@bib0080]) and the spontaneous recovery of encephalitis in patients with COVID-19 also supports the idea of transient SARS-CoV-2 dissemination and extremely low CSF viral load ([@bib0085]). Thus, considering the sole report of a severe case of meningoencephalitis with detectable SARS-CoV-2 RNA in CSF ([@bib0055]), likely presenting a low viral load since just one of two RT-qPCR assays turned positive at a cycle threshold of 37, we can assume that whether SARS-CoV-2 is detectable in CSF, it may depend on disease severity, the time of sample collection or the sensitivity of the molecular test used. On the other hand, herpes simplex viruses 1 and 2 (HSV-1/2), varicella zoster virus (VZV), and enterovirus are responsible for the greatest number of CNS infection in immunocompetent hosts ([@bib0020]). Therefore, CSF investigation of COVID-19 patients presenting with GBS or CNS manifestations to exclude concurrent neuroinfection with other neurotropic viruses should be encouraged.Table 1SARS-CoV-2 detection in CSF of COVID-19 patients with neurological manifestations.Table 1**Neurological outcomesNumber of casesDays between CSF withdrawn and symptoms onsetRT-qPCR in nasopharyngeal swabRT-qPCR in CSFOther viruses tested negative in CSFReferences**Meningoencephalitis (1), Encephalitis (1), Facial palsy (2), delirium (2), intracranial hypertension (1), new daily persistent headache (1)^*a*^82 to 10positivenegativeHSV-1/2, VZV, CMV, EBV, HHV-6, Influenza A and B virusesThis study^*b*^Meningoencephalitis19negative^*c*^positiven.i.[@bib0055]Meningoencephalitis25 and 17positivenegativeEnterovirus, HSV-1/2, VZV, CMV, HHV-6, Parechovirus[@bib0015]Autoimmune meningoencephalitis6n.i.positivenegativeCommon seasonal viruses (not specified)[@bib0030]Acute disseminated encephalomyelitis1n.i.positivenegativeNeurotropic viruses (not specified)[@bib0090]GBS59 to 134 positive and 1 negative^*c*^negativen.i.[@bib0080]GBS110positivenegativeEnterovirus, HSV-1/2, VZV, CMV, HHV-6, Parechovirus[@bib0025]GBS110positivenegativen.i.[@bib0060]GBS17positivenegativen.i.[@bib0010]Facial diplegia (GBS variant)111positivenegativen.i.[@bib0040]Perfusion abnormalities in brain MRI7n.i.positivenegativen.i.[@bib0035]Acute cerebrovascular disease27 and 10positivenegativen.i.[@bib0005]Encephalitis119positivenegativen.i.[@bib0085]Encephalitis15positivenegativeEnterovirus, HSV-1/2, VZV, EBV, HHV-6, HHV-8, Adenovirus[@bib0070][^1]Table 2Characteristics of the CSF of COVID-19 patients with distinct neurological manifestations.Table 2**Neurological manifestationsNumber of casesCSF cell count (cells/μL)**^***a***^**Mononuclear cells (%)Polymorphonuclear cells (%)Protein (mg/dL)**^***b***^**Glucose (mg/dL)**^***c***^**References**Meningoencephalitis118100060.043.0This studyEncephalitis12100023.096.0This studyFacial palsy23100040.556.5This studyDelirium23100051.5115.0This studyIntracranial hypertension11100019.056.0This studyNew daily persistent headache11100027.063.0This studyMeningoencephalitis1128317n.i.n.i.[@bib0055]Meningoencephalitis21993746.4normal[@bib0015]Autoimmune meningoencephalitis60\--69.4116.3[@bib0030]Acute disseminated encephalomyelitis1normaln.i.n.i.normalnormal[@bib0090]GBS50^*d*^n.i.n.i.83.2^*e*^normal[@bib0080]GBS1n.i.n.i.n.i.n.i.n.i.[@bib0025]GBS10\--108n.i.[@bib0060]GBS19n.i.n.i.54n.i.[@bib0010]Facial diplegia (GBS variant)10\--44n.i.[@bib0040]Perfusion abnormalities in brain MRI70\--normal (except for one patient)n.i.[@bib0035]Acute cerebrovascular disease2n.i.n.i.n.i.n.i.n.i.[@bib0005]Encephalitis11n.i.n.i.2756.5[@bib0085]Encephalitis118n.i.n.i.69.6n.i.[@bib0070][^2]
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[^1]: *Notes.* CSF, cerebrospinal fluid; RT-qPCR, reverse transcriptase quantitative polymerase chain reaction; HSV-1/2, herpes simplex virus 1 and 2; VZV, varicella zoster virus; EBV, Epstein-Barr virus; CMV, cytomegalovirus; HHV-6, human herpes virus 6; GBS, Guillain-Barré Syndrome; n.i., not informed. ^*a*^ Number of cases of each neurological manifestation observed in our cohort of COVID-19 patients is shown inside parenthesis; ^*b*^ Detection of SARS-CoV-2 RNA was carried out with the Biomanguinhos (E + P1) RT-qPCR kit (FIOCRUZ, Brazil); ^*c*^ Confirmed by serologic test in serum sample.

[^2]: *Notes.* Mean values are shown for cerebrospinal fluid (CSF) cell counts, protein, and glucose levels in groups of neurological manifestations with more than 1 case; ^*a*^ Normal CSF cell counts: ≤5 cells/μL; ^*b*^ Normal range for CSF protein: 15 -- 40 mg/dL; ^*c*^ Normal range for CSF glucose: 40 -- 80 mg/dL; ^*d*^ Five patients presented no cells and one patient had 3 cells/mm^3^. ^*e*^ Two patients had normal CSF protein levels without specified values; therefore, a concentration of 30 mg/dL was assumed to calculate a mean value. GBS, Guillain-Barré Syndrome; n.i., not informed.
